2016-11-01
Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - Commentary
Publication
Publication
Multiple Sclerosis: clinical and laboratory research , Volume 22 - Issue 13 p. 1653- 1654
Additional Metadata | |
---|---|
doi.org/10.1177/1352458516661240, hdl.handle.net/1765/94312 | |
Multiple Sclerosis: clinical and laboratory research | |
Organisation | Department of Neurology |
Hintzen, R. (2016). Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - Commentary. Multiple Sclerosis: clinical and laboratory research, 22(13), 1653–1654. doi:10.1177/1352458516661240 |